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2Abstract
Cerebral ischemia causes long-lasting protein synthesis inhibition that is believed to 
contribute to brain damage. Energy depletion promotes translation inhibition during ischemia 
and the phosphorylation of eukaryotic initiation factor 2D (eIF2D) is involved in the 
translation inhibition induced by early ischemic reperfusion. However, the molecular 
mechanisms underlying prolonged translation downregulation remain elusive. NMDA 
excitotoxicity is also involved in ischemic damage, as  exposure to NMDA impairs translation 
and promotes the synthesis of nitric oxide (NO), which can also inhibit translation. Here we 
investigated whether NO was involved in NMDA-induced protein synthesis inhibition in 
neurons and studied the underlying molecular mechanisms. NMDA and the NO-donor 
DEA/NO both inhibited protein synthesis and this effect persisted after a 30-min-exposure. 
Treatments with NMDA or NO promoted calpain-dependent eIF4G cleavage and 4E-BP1 
dephosphorylation and also abolished the formation of eIF4E/eIF4G complexes, however 
they did not induce eIF2D phosphorylation. Although NO synthase (NOS) inhibitors did not 
prevent protein synthesis inhibition during 30-min NMDA exposure, they did abrogate the 
persistent inhibition of translation observed after NMDA removal. NOS inhibitors also 
prevented NMDA-induced eIF4G degradation, 4E-BP1 dephosphorylation, eIF4E-eIF4G 
binding reduction and cell death. Although the calpain inhibitor calpeptin blocked NMDA-
induced eIF4G degradation, it did not prevent 4E-BP1 dephosphorylation, which precludes 
eIF4E availability, and thus translation inhibition was maintained. This study suggests that 
eIF4G integrity and hyperphosphorylated 4E-BP1 are needed to ensure appropriate translation 
in neurons. In conclusion, our data show that NO mediates NMDA-induced persistent 
translation inhibition and suggest that deficient eIF4F activity contributes to this process.
INTRODUCTION
Brain ischemia induces early and deep inhibition of protein synthesis that is persistent in 
vulnerable neurons such as CA1 hippocampal and striatal neurons [1-3]. In this regard, long-
lasting inhibition of protein synthesis is one of the alterations that best correlates with 
neuronal injury after ischemia. Indeed, translation recovery is associated with survival, 
whereas neurons unable to overcome protein synthesis blockade are destined to die [4]. 
Translation is mainly inhibited via regulation of the initiation and elongation steps, by 
impairing the activity of certain eukaryotic initiation or elongation factors (eIFs or eEFs). 
Modulation of the phosphorylation status and/or degradation of these proteins account for 
their inactivation. For instance, changes in the phosphorylation status of eIF2Į, 4E-BP1 or 
eEF2 are known to modulate the rate of protein synthesis [5]. Phosphorylation of eIF2Į by the 
double-stranded RNA-activated protein kinase-like endoplasmic reticulum (ER) kinase 
(PERK) is sufficient to abrogate protein synthesis soon after reperfusion following an 
ischemic episode [6-9]. In addition, a number of other factors are affected. For instance, 
depletion of ATP activates eEF2 kinase through AMP kinase in cortical neurons and slows 
elongation [10]. Furthermore, global cerebral ischemia leads to eIF4G and eIF4E breakdown 
[11-13]. Production of NO bursts after ischemia and NO is involved in inflammation, cerebral 
damage [14] and protein synthesis reduction through eIF2D phosphorylation [15-17]. 
Likewise, excitotoxicity is one of the main promoters of neuronal loss after an ischemic 
episode, and is also known to inhibit protein synthesis [18-21]; however the underlying 
mechanisms are not fully elucidated. The rise in intracellular calcium induced by glutamate 
activates eEF2 kinase, which in turn phosphorylates eEF2 and results in the transient blockade 
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3of elongation [18]. The increase in cytosolic calcium concentration following NMDA 
activates the cysteine protease calpain [22]. eIF4G, the scaffolding protein that enables the 
assembly of eIF4E and eIF4A with the mRNA and the ribosomal 40S subunit is a substrate of 
calpain [13], and is thus a possible target of NMDA. However, most studies of eIF4G 
cleavage have reported that eIF4G is the target of caspase-3 in apoptotic conditions (reviewed 
in [23]).  Caspase-3 cuts eIF4GI at two sites to generate three fragments, as referred to as: 
Fragments of Apoptotic cleavage of eIF4G (FAG): N-FAG, M-FAG and C-FAG, 
corresponding to the N-, middle- and C-terminal parts of the protein, respectively (reviewed 
in [23]). M-FAG533-1176 is the only fragment that remains able to promote some cap-dependent 
translation. Therefore, proteolysis of eIF4G is presumably associated with the switch from 
cap-dependent to cap-independent translation and favours, for example, the translation of 
specific internal ribosome entry site (IRES)-containing mRNAs [23]. Unlike with FAG, the 
role of eIF4G fragments resulting from calpain activity has not been explored. 
eIF4E binding protein 1 (4E-BP1) is another key regulator in protein synthesis because it 
associates to eIF4E [24]. In cell cultures, insulin, amino acids and rapamycin modulate the 
phosphorylation status of 4E-BP1 through mammalian target of rapamycin (mTOR) 
signalling [25,26]. In the hypophosphorylated form, 4E-BP1 competes with the binding site of 
eIF4G and sequesters eIF4E, whereas the hyperphosphorylated J form dissociates from 
eIF4E, enabling it to engage with other components of the eIF4F complex [24,27-31]. 
Therefore, proteolysis of eIF4G together with dephosphorylation of 4E-BP1 precludes the 
formation of eIF4F complexes [32] that may reduce the cap-mRNA translation.  
There is compelling evidence of crosstalk between NO and NMDA. In pure neuron cultures, 
uncoupling between the NMDA receptor and nNOS signaling pathways [33] and 
pharmacological inhibition of nNOS [34] strongly prevent neuronal death after an excitotoxic 
challenge. Reciprocally, production of NO by iNOS in activated glia leads to neuronal death, 
which is prevented by MK-801, a NMDA receptor antagonist [35-37], thus suggesting that 
NO leads to glutamate release [38] in a positive feed-back loop. Furthermore, NO challenge 
triggers excitotoxicity in cerebellar neurons [39]. The mechanisms responsible for NO 
toxicity are not completely elucidated but energy depletion is likely involved. NO induces a 
fast depolarisation of the mitochondria, which leads to reduced ATP production [40]. In 
addition, NO exposure triggers the activation of PARP that leads to ATP consumption and 
may therefore account for energy depletion [41].
Here we addressed the molecular mechanisms underlying NMDA-mediated long-term 
inhibition of protein synthesis in neuronal cultures, and considered whether NO is involved in 
this process. 
MATERIALS AND METHODS 
Materials
All products for culture, except MEM, were purchased from Invitrogen (Paisley, Scotland, 
UK). ATP bioluminescent assay kit, somatic cell ATP releasing agent, chemicals and reagents 
were obtained from Sigma-Aldrich (Alcobendas, Spain), unless otherwise stated. 
Diethylamine/Nitric oxide sodium complex (DEA/NO) and NZ-propyl-L-arginine were 
purchased from Tocris (Avonmouth, UK). The calpain inhibitors calpeptin and MDL28170, 
as well as rapamycin were from Calbiochem (LaJolla, CA, USA). The non-specific nitric 
oxide synthase (NOS) inhibitor NZ-nitro-L-arginine methyl ester (L-NAME) and the 
neuronal specific NOS (nNOS) inhibitor NZ-propyl-L-arginine (NPLA) were purchased from 
Sigma-Aldrich. The mouse antibodies against eIF4E and STAT3 were from BD Transduction 
Laboratories (Heidelberg, Germany). The goat antibodies against eIF4G (N-20) and anti-
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4eIF2D were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Rabbit anti-
phospho-eIF2D (Ser51) was from Epitomics (Burlingame, CA, USA) and mouse anti-spectrin 
was from Chemicon (Temecula, CA, USA). Anti-4E-BP1 antibody was obtained from Cell 
Signaling Technology (Beverly, MA, USA). Anti-mouse, anti-goat and anti-rabbit HRP-
conjugated antibodies were from Amersham (Buckinghamshire, England). Complete protease 
inhibitor cocktail and the antibody against E-tubulin were from Boehringer Mannheim 
(Germany). L-[4,5-3H]leucine (S.A. = 73 Ci/mmol) and 7-methyl GTP-Sepharose were 
purchased from Amersham (Buckinghamshire, England).
Cell cultures and treatments 
Mixed primary cortical cultures of neurons and glia were prepared from 18-day-old Sprague-
Dawley rat embryos (Charles River, France), as previously described [20]. Animals were 
anaesthetized and killed by cervical dislocation. All procedures were approved by the Ethical 
Committee for Animal Use (CEEA) at the University of Barcelona. Neuron-enriched cultures 
were prepared as mixed cultures, but ARA-C was added on day in vitro 4 and then in the 
subsequent partial medium changes on days in vitro 7 and 10 to limit glial proliferation. Cells 
were seeded on 24-well plates at a density of 3680 cells/mm2. For the ATP content 
measurement, cells were seeded on 6-well plates. All experiments were performed on day in 
vitro 11-13 cultures. 
DEA/NO was prepared as a 20 mM stock in NaOH pH10 to avoid NO release and stored at -
20ºC for further use. A 2 mM DEA/NO solution in NaOH pH10 was prepared 
extemporaneously and added to the culture medium in order to achieve a final concentration 
of 4-40 µM. Cells were exposed for 30 min to DEA/NO and medium was thereafter replaced 
with MEM supplemented with B27 and gentamycin. Excitotoxic lesion was performed by 
treating cultures for 30 min with 35 µM NMDA. NOS inhibitors (L-NAME + NPLA) were 
added simultaneously to NMDA and also after medium change. Calpain inhibitors were 
added at 30 PM, unless otherwise stated, 1 h before NMDA or DEA/NO and also after 
medium change. Thapsigargin at 1 or 10 PM was added for 30 min and rapamycin at 1 or 2 
PM for 3 h with no previous medium change. Calpeptin, MDL28170, thapsigargin and 
rapamycin were dissolved in DMSO.  
Measurement of LDH activity 
Cell death was estimated 24 h after the lesion by measuring the activity of lactate 
dehydrogenase (LDH) released in the medium as previously described [20]. Briefly, the 
decrease in 0.75 mM NADH absorbance at 340 nm was followed in a phosphate buffer (50 
mM, pH 7.4) in the presence of 4.2 mM pyruvic acid as substrate. The kinetic assay of NADH 
consumption was monitored for 4 min and the slope values of decreased absorbance at 340 
nm (negative values) were converted to positive values and expressed in arbitrary units (AU).
Propidium iodide nuclear staining 
Cells were treated for 30 min with 35 µM NMDA and then fixed and stained with propidium 
iodide (PI) 24 h later as previously described [20]. PI-positive nuclei were counted in three 
fields per well and the sum of the three, corresponding to a total area of 0.4416 mm2 was 
calculated. The result was expressed as PI positive cells/mm2.
Incorporation of [3H]leucine into proteins 
Culture medium was withdrawn and cells were incubated in 300 µl of MEM/B27 containing 
396 PM of unlabeled leucine and 4 PCi/ml [3H]leucine for 30 min at 37ºC. NMDA or 
DEA/NO were added immediately after the [3H]leucine to evaluate their effect on protein 
synthesis at 30 min (0.5 h in figures). To assess protein synthesis 2 h after transient exposure 
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5to NMDA or DEA/NO, cells were incubated with NMDA or DEA/NO for 30 min, medium 
was changed to MEM/B27 and, 90 min later, cells were incubated with [3H]leucine for 30 
min as described above. Medium was removed, proteins were precipitated with trichloroacetic 
acid and lysates were processed as previously described [20] for the determination of 
[3H]leucine incorporated into proteins. Results were expressed as dpm in the TCA 
fraction/mg protein/min. 
Measurement of ATP levels 
After drug treatments, cells were washed with cold PBS and collected in a 5 mM EDTA, 0.1 
M Na2HPO4, pH 7.5 buffer. After a 5 min spin at 590 X g at 4ºC, pellets were resuspended in 
200 µl of the same buffer, sonicated and centrifuged again for 15 min at 10 000 X g at 4ºC. 
ATP content was determined in the fresh supernatants using an ATP bioluminescent assay kit 
and following manufacturer’s instructions. Samples were run together with a 0.05-8 µM ATP 
standard curve and luminescence was monitored in an Orion microplate luminometer 
(Berthold detection system). Relative light units (RLU) were converted to pmols of ATP and 
results were expressed as nmol ATP/mg protein. 
Western blot 
Neuron-enriched cultures were treated with NMDA, NMDA+NOS inhibitors, or DEA/NO for 
30 min. Ninety minutes later, cultures were washed with cold 10 mM phosphate-buffered 
saline (PBS) and harvested in radio-immunoprecipitation (RIPA) lysis buffer (10 mM PBS, 
1% Igepal AC-630, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate) 
supplemented with a protease inhibitor cocktail (Complete) and 1 mM sodium orthovanadate. 
Protein content was determined by the Bradford assay (Bio-Rad Laboratories, München, 
Germany). Thirty µg of proteins was separated by electrophoresis on 7%, 12% or 17% 
polyacrylamide gels (for spectrin-eIF4G, eIF2D and 4E-BP1, respectively) in denaturing 
conditions and transferred to 0.2 µm polyvinylidene difluoride Immun-Blot membranes (Bio-
Rad Laboratories, Hercules, CA, USA). Membranes were incubated overnight at 4ºC with the 
following primary antibodies: goat anti-eIF4G diluted 1:500, goat anti-eIF2D, rabbit anti-
phospho-eIF2D (Ser51), rabbit anti-4E-BP1 diluted 1:2000, mouse anti-spectrin diluted 
1:4000, mouse anti-STAT3 and mouse anti-eIF4E diluted 1:1000. After two washes in Tris 
buffer containing Tween-20 (T-TBS), membranes were then incubated for 1 h at room 
temperature with either anti-rabbit, anti-mouse or anti-goat horseradish peroxidase-conjugated 
antibody. The reaction was visualized using a chemiluminescence detection system based on 
the luminol reaction. Autoradiograms were scanned with a GS-800 Densitometer scanner 
(Bio-Rad) and band density was quantified with the Quantity One image analysis software 
(Bio-Rad). Molecular weight markers are indicated in kDa on the left side of some of the 
blots shown in the Figures. For the analysis of eIF2D phosphorylation the 
phosphorylated/total protein ratio was calculated for each sample. Since the molecular 
weights of spectrin and eIF4G are 240 and 220 kDa, respectively, we decided to use the 90 
kDa protein STAT3 of higher MW than tubulin, to check for equal loading, since none of the 
treatments affected STAT3 expression (not shown). The densities of the 150-145 kDa bands 
corresponding to cleaved spectrin were quantified together. The spectrin/STAT3 and 
eIF4G/STAT3 ratios were calculated for each sample. Data from all quantifications are 
expressed as a percentage of controls. In the case of 4E-BP1, the proportion of each 
phosphorylated form (D, E and J) was calculated as a percentage of total 4E-BP1 as in [32].
Determination of the formation of eIF4E/eIF4G and eIF4E/eIF4E-B1 complexes
After the different treatments, cells were washed with buffer A containing 20 mM Tris-HCl, 
pH 7.6, 1 mM dithiothreitol, 1 mM EDTA, 1 mM PMSF, 1 mM benzamidine, 120 mM KCl, 
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610 Pg/ml leupeptin, 1 Pg/ml pepstatin A, 10 Pg/ml antipain, 50 mM sodium fluoride, 10 mM 
glycerophosphate and 10 mM sodium molybdate; they were then lysed with buffer A 
containing 0.5% Igepal AC-630 and 0.1% triton X-100. Cell extracts were spun at 12000 X g 
for 10 min at 4ºC and the supernatants were collected and frozen at -80ºC for further use. Two 
hundred Pg of proteins was incubated with 7-methylguanosine triphosphate (m7GTP)-
Sepharose for 45 min at 4ºC in buffer A containing 0.1 mM GTP. Proteins were eluted from 
m7GTP-Sepharose with SDS loading buffer and subjected to 7.5%-17% SDS-PAGE and 
Western blot. Membranes were incubated separately with antibodies against eIF4G, eIF4E 
and 4E-BP1.
Statistical analysis 
Results are expressed as mean r SEM and the number of replicates (n) is indicated in the 
legend of each figure. Unless indicated, one-way analysis of variance (ANOVA) with the 
Bonferroni post-hoc test was performed to evaluate significant differences between groups. 
Kruskal-Wallis analysis followed by Dunn’s test for multiple comparisons was used to 
compare groups with non-homogenous variance. One symbol indicates P<0.05, two P<0.01 
and three P<0.001. 
RESULTS
NOS inhibitors protected against NMDA toxicity in mixed and neuron-enriched 
cultures.
One of our objectives was to determine whether NO participates in NMDA-induced inhibition 
of protein synthesis in our primary cultures. First, we confirmed that NMDA toxicity was 
dependent on NO. When testing the effect of several NOS inhibitors we found that the 
combination of the non-specific NOS inhibitor L-NAME with the specific nNOS inhibitor 
NPLA at 2 mM and 100 PM, respectively provided almost complete protection against 
transient (30 min) exposure to 35 PM NMDA in mixed neuron/glia and neuron-enriched 
cultures, as assessed by lactate dehydrogenase activity and propidium iodide staining assays 
(Figs. 1A and 1B). Further experiments were therefore performed with the NAME+NPLA 
combination of NOS inhibitors (referred to as NOS inhibitors in the text). Treatment with the 
above concentrations of NOS inhibitors did not affect neuronal viability (Fig. 1A). To check 
for direct NO toxicity, i.e. not induced by NMDA, we performed a dose-response study with 
DEA/NO, an NO-donor. DEA/NO was applied for 30 min and toxicity was assessed at 24 h. 
At 40 µM DEA/NO induced similar toxicity to treatment with 35 µM NMDA (Fig. 1C) and 
this concentration of DEA/NO was therefore selected to perform further experiments.  
NMDA and NO induced protein synthesis failure 
We have previously demonstrated that NMDA decreases the protein synthesis rate after 1 h 
exposure [20]. Here we explored whether transient exposure to NMDA caused long-lasting 
inhibition of protein synthesis. A time-course study showed that NMDA inhibited by 52 and 
43% the incorporation of [3H]leucine into proteins after 30-min exposure in mixed (Fig. 2A) 
and neuron-enriched cultures (Fig. 2B), respectively. After removal of NMDA, protein 
synthesis partially recovered but remained significantly lower than in controls 2 h later (i.e. 90 
min after NMDA removal) in both mixed (Fig. 2A) and neuron-enriched cultures (Fig. 2B). 
NOS inhibitors were ineffective at 30 min (during NMDA exposure) but did promote 
complete recovery of protein synthesis at 2 h. Treatment with NOS inhibitors alone had no 
effect on protein synthesis (Fig. 2B). DEA/NO also led to a slight reduction of protein 
synthesis (less than 20%) at the end of a 30-min exposure and the effect was more 
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7pronounced 2 h later (33% decrease) in neuron-enriched cultures (Fig. 2C). Altogether these 
data suggest that NO impairs translation and contributes to the late phase of protein synthesis 
inhibition induced by NMDA. 
NMDA and NO induced a moderate decrease in ATP content and did not regulate the 
phosphorylation of eIF2D
ATP depletion can induce endoplasmic reticulum stress, which leads to phosphorylation of 
eIF2D and subsequent inhibition of protein synthesis [15,42]. Here we evaluated ATP content 
after the treatments to determine whether ATP depletion was involved in the observed 
inhibition of protein synthesis. NMDA caused a 26% reduction of ATP levels at the end of 
the 30-min exposure, and this effect was maintained 2 h later (Fig. 3A). Although DEA/NO 
reduced ATP content to 53% after 30-min exposure, this effect was not significantly different 
from controls 2 h later (Fig. 3B), thus indicating that in contrast to NMDA the action of NO 
on ATP is not long-lasting. NOS inhibitors did not prevent the ATP decrease 2 h after NMDA 
exposure (Fig. 3C), and this illustrates that NO was not involved in the persistent ATP 
reduction after NMDA. Our data suggest that the late protein synthesis inhibition caused by 
NMDA is not mediated by the corresponding ATP reduction.  
Phosphorylated eIF2D binds to the GDP/GTP exchanger eIF2B and inhibits its function 
([reviewed in [30]). The inability to restore the binding of GTP to eIF2 prevents the formation 
of new eIF2·GTP·Met-tRNAi ternary complexes and consequently protein synthesis is 
inhibited. NMDA and NO did not induce eIF2D phosphorylation on Ser51 (Figs. 3D and 3E), 
indicating that eIF2 activity was not inhibited. In order to determine whether our cultures 
might show increased phosphorylation of eIF2Į, neurons were treated for 30 min with 
thapsigargin. This endoplasmic reticulum stress inducer is known to cause eIF2Į
phosphorylation through PERK activation. Figure 3F shows that thapsigargin triggers eIF2Į
phosphorylation when compared to control cells. 
NMDA and NO led to calpain activation and eIF4G proteolysis
NMDA is known to induce cytosolic calcium increase [10,20] during the period of exposure. 
As expected, NMDA activated calpain, a calcium-dependent cysteine protease, which was 
assessed by the proteolysis of D-spectrin (Figs. 4A and 4C). The 240 kDa full-length protein 
is processed into 150 and 145 kDa fragments by calpain and to 150 kDa and 120 kDa 
fragments by caspase-3 [43]. NMDA generated the formation of the 145-150 kDa fragments 
only (Fig. 4A), this being indicative of calpain-dependent hydrolysis. Furthermore, eIF4G 
was cleaved 2 h after NMDA exposure (39% decrease, P<0.05; Figs. 4A and 4C). Proteolysis 
of both spectrin and eIF4G was completely blocked in the presence of NOS inhibitors (Figs. 
4A and 4C), thus indicating an NO-dependent mechanism. In agreement with a previous 
report [39], NO dramatically stimulated calpain and reduced eIF4G levels by 52% (Figs. 4B 
and 4D). Several calpain inhibitors (not shown) were then used to determine the contribution 
of calpain to eIF4G processing, and we found that two of them, calpeptin and MDL28170, 
completely inhibited calpain activation and blocked the eIF4G degradation induced by 
NMDA (Figs. 5A and 5C) and DEA/NO (Figs. 5B and 5D). Therefore, eIF4G degradation 
was totally dependent on calpain activation.
NMDA and DEA/NO induced the dephosphorylation of 4E-BP1 and abrogated the 
formation of eIF4F complexes 
The formation of eIF4F complexes plays a key role in the regulation of translation initiation. 
Since eIF4E is a component of the eIF4F complex and it is a rate-limiting translation factor 
for cap-mRNA, we measured its level of expression, observing that none of the treatments 
altered its cell content (Fig. 6A).  
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8The phosphorylation status of 4E-BP1 also governs the formation of eIF4F complexes. 4E-
BP1 resolves into three electrophoretic forms J, E and D of increasing migration velocity. 
Only the hyperphosphorylated J form of 4E-BP1 does not bind eIF4E [31] and therefore it 
increases the availability of eIF4E to interact with eIF4G. We studied the phosphorylation of 
4E-BP1 and performed a semi-quantitative analysis of the proportion of J, E and D forms with 
respect to total 4E-BP1 (Fig. 6B and Table 1). NMDA was observed to promote a shift from 
the J form to the D form (Table 1), an effect that was abrogated by NOS inhibitors (Fig. 6B 
and Table 1). Furthermore, DEA/NO induced the dephosphorylation of 4E-BP1, illustrated by 
a decrease in the J form and an increase in the D form, which is the band of lowest mobility 
(Fig. 6B and Table 1). In contrast, none of the treatments affected the E form.  
Since eIF4G and 4E-BP1 compete for the same binding site in eIF4E, we evaluated the 
proteins bound to eIF4E after its purification by m7GTP-sepharose affinity chromatography. 
DEA/NO and NMDA almost completely abolished the interaction between eIF4G and eIF4E, 
and the NMDA effect was prevented by NOS inhibitors (Fig. 6C). 
We also studied whether calpain inhibitors influenced the phosphorylation status of 4E-BP1. 
Calpeptin and MDL28170 did not reverse the dephosphorylation of 4E-BP1 induced by 
NMDA and DEA/NO, respectively (Fig. 6B and Table 1). Moreover, calpeptin decreased the 
J form and enhanced the formation of the D form compared to NMDA alone (Fig. 6B and 
Table 1). When the protein synthesis rate was measured, we observed that none of the calpain 
inhibitors prevented the blockade of protein synthesis induced by NMDA or DEA/NO (Fig. 
6D), thus suggesting that the prevention of eIF4G cleavage alone is not sufficient to abrogate 
the inhibition of protein synthesis. In contrast, NOS inhibitors that blocked eIF4G processing 
and dephosphorylation of 4E-BP1 did promote the complete recovery of translation (Figs. 2B, 
4C and 6B). In addition, we observed that none of the calpain inhibitors rescued neurons from 
death (Fig. 6E), suggesting that survival is compromised when the normal rate of protein 
synthesis is not achieved.
Rapamycin reduced the formation of eIF4F complexes and inhibited protein synthesis in 
a similar way to NMDA   
In order to determine whether hypophosphorylation of 4E-BP1 was by itself sufficient to 
reduce the formation of eIF4F complexes in the absence of eIF4G degradation, we incubated 
neurons with rapamycin, an inhibitor of the 4E-BP1 kinase mTOR (reviewed in [30]). Three 
hours after addition of rapamycin we observed a dephosphorylation of 4E-BP1 but no loss of 
eIF4G (Fig. 7A). When we looked at the amount of eIF4G bound to eIF4E after m7GTP-
sepharose affinity chromatography, we found that rapamycin induced a dose-dependent 
inhibition of eIF4G binding to eIF4E (Fig. 7B) that correlated with a decrease in protein 
synthesis (Fig. 7C) of similar proportions to that achieved with NMDA (Fig. 6D).
DISCUSSION 
The present study investigated the mechanisms underlying excitotoxicity-mediated translation 
repression. In particular, we explored the contribution of eIF4G proteolysis and 4E-BP1 
dephosphorylation to NMDA- and DEA/NO-induced protein synthesis inhibition. To our 
knowledge, this is the first study to report molecular changes in translation factors that might 
be involved in the long-lasting inhibition of protein synthesis after transient exposure to 
NMDA. We showed that neurons can withstand a transient blockade of translation with 
limited neuronal loss, and also provided evidence that protein synthesis recovery closely 
correlates with neuronal survival, as is observed in animal models of stroke [1]. Indeed, the 
inactivation of NOS enabled full recovery of global protein synthesis, along with an almost 
complete rescue from NMDA-induced neurotoxicity; this latter finding has been previously 
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9reported by other groups [44,45]. Interestingly, NOS inhibitors were able to prevent the 
delayed but not the initial inhibition of protein synthesis following NMDA exposure. 
Similarly, ischemic preconditioning suppresses persistent but not acute inhibition of 
translation (reviewed in [46]).
 NOS inhibitors did not impede NMDA-induced ATP reduction, despite the fact that 
they promoted a complete recovery of protein synthesis. Therefore, the moderate decrease in 
ATP after NMDA and DEA/NO treatments is unlikely to be the cause of protein synthesis 
inhibition. This result is in agreement with previously published data showing that severe 
protein synthesis inhibition precedes ATP reduction after treatment with an NO-donor [17]. 
Furthermore, suppression of protein synthesis occurs in the penumbra where ATP levels are 
maintained in transient focal ischemia [3]. Interestingly, our data are in accordance with 
studies suggesting that transient inhibition of protein synthesis is not lethal, whereas the 
persistent phase of translation suppression is related to neurodegeneration [18,46-48].  
Release of calcium from ER stores through blockade of Ca2+/ATPase with 
thapsigargin [17] was shown to induce protein synthesis alterations due to phosphorylation of 
eIF2D. Glutamate also mobilizes Ca2+ from ER reservoirs but depresses protein synthesis in 
an eIF2D phosphorylation-independent manner [19], in agreement with our data. We did not 
detect phosphorylation of eIF2D after exposure to DEA/NO, a fast NO-releasing complex, in 
contrast to previous observations in neuroepithelial cells [16]. S-nitroso–N-
acetylpenicillamine (SNAP), a slow NO-releasing agent, has been shown to mobilize 
thapsigargin-sensitive calcium ER stores in neurons [17] and to phosphorylate eIF2D
similarly to thapsigargin in neuroblastoma [15]. The shorter exposure time, faster NO release 
and lower concentration of NO-donor used in our study may explain the discrepancies with 
those studies. Therefore, under our experimental conditions DEA/NO inhibited translation by 
a mechanism that was independent of eIF2D phosphorylation, at least in the late phase. Our 
data suggest that NO does not contribute to the initial inhibition of protein synthesis by 
NMDA, but rather takes part in delayed translation deterioration.
Calpain activation and subsequent proteolysis of its substrates is known to occur after 
excitotoxicity in neurons [22,39,43]. While some reports show an attenuation of NMDA 
toxicity with pharmacological inhibitors of calpain [22], others have found no protection [43], 
as we did in the present study. Nevertheless, we found that calpain was responsible for eIF4G 
breakdown after exposure to NMDA or DEA/NO, in accordance with previous observations 
in the ischemic brain [13]. Proteolysis of several translation factors has been reported, mainly 
in apoptotic conditions. Research has shown that eIF2Į and 4E-BP1 are the substrate for 
caspase-3 (reviewed in [23]), while eIF4E and 4E-BP1 are the substrate for calpain in vitro
[12,49]. However, to the best of our knowledge there is no evidence that eIF4E and 4E-BP1 
are cleaved by calpain in vivo [12,49].  Here, we did not observe any degradation of eIF2D,
eIF4E or 4E-BP1, suggesting that calpain specifically processed eIF4G in our settings. The 
eIF4G fragment generated by calpain cleavage does not bind to eIF4E, thus precluding the 
formation of eIF4F complexes, as shown in both the present study and a model of global 
cerebral ischemia [32]. Therefore, it is likely that the strong proteolysis of eIF4G contributed 
to impaired translation in our experimental conditions.
 The binding of 4E-BP1 to eIF4E also compromises the association of eIF4F 
components [24]. We observed that NMDA and DEA/NO insults led to the 
dephosphorylation of 4E-BP1, which is expected to facilitate its binding to eIF4E. A similar 
process has been described after global ischemia and was shown to cause a deficit in 
eIF4E/eIF4G complexes and, therefore, to contribute to translation inhibition [32]. NOS 
inhibitors enabled the complete recovery of protein synthesis by preventing eIF4G proteolysis 
and by precluding the dephosphorylation of 4E-BP1. The lack of protein synthesis recovery in 
the presence of a normal amount of eIF4G (in the presence of calpain inhibitors) suggests that 
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the hypophosphorylation of 4E-BP1 is sufficient to reduce the protein synthesis rate. This 
result is supported by the data obtained with rapamycin. Rapamycin that dephosphorylated 
4E-BP1 but maintained eIF4G integrity reduced the rate of protein synthesis. The rapamycin-
induced inhibition of translation correlated with the reduced formation of eIF4E/eIF4G 
complexes. eIF4E is crucial for cap-dependent translation initiation and is a mandatory 
element of the eIF4F complex since it functions as the cap-binding protein. Reduced 
availability of eIF4E resulting from protease-mediated degradation or trapping by 4E-BP1 
would severely compromise cap-mRNA translation. Therefore, eIF4E is a rate-limiting factor 
and its sequestration by 4E-BP1 might slowdown the process of translation. The lower 
amount of full-length eIF4G may worsen the process by decreasing the probability of eIF4E-
eIF4G binding. Our data suggest that preventing eIF4G degradation and 4E-BP1 
dephosphorylation are necessary to unlock translation repression. The maintenance of eIF4G 
levels while 4E-BP1 is hypophosphorylated is not sufficient to prevent protein synthesis 
inhibition. Our results are in agreement with research showing that ischemic tolerance, which 
promotes translation recovery, tends to prevent eIF4G processing and to favour the 
phosphorylation of 4E-BP1 [47,50].
Since eIF4G and eIF4E play a key role in the translation of cap-mRNAs, we propose 
that limited availability of both proteins accounts for long-lasting translation failure 
(summarized in Figure 8) and contributes to neuronal loss after NMDA and NO challenges. 
Further studies are required to unravel the mechanisms controlling 4E-BP1 
dephosphorylation.
Acknowledgements: 
The authors would like to thank Araceli Salinas and Elisabet Gomez for their excellent 
technical assistance and the Language Advice Service from the University of Barcelona for 
revising the English. VP is a recipient of a Ramon y Cajal grant and MFN a recipient of a FPI 
grant from the Spanish Ministry of Education and Science (MEC). This study was supported 
by grants FIS05/0271 from the Spanish Ministry of Health and SAF2005-05793-C01 from the 
Ministry of Education and Science. 
Biochemical Journal Immediate Publication. Published on 16 Jan 2008 as manuscript BJ20071060
TH
IS
 IS
 N
O
T 
TH
E 
FI
NA
L 
VE
RS
IO
N 
- s
ee
 d
oi
:1
0.
10
42
/B
J2
00
71
06
0
St
ag
e 2
(a)
 PO
ST
-PR
INT
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2008 The Authors Journal compilation © 2008 Biochemical Society
11
REFERENCES
1 Hossmann, K.A. (1993) Disturbances of cerebral protein synthesis and ischemic cell 
death. Prog. Brain Res. 96 161-177 
2 Dienel, G.A., Pulsinelli, W.A. and Duffy, T.E. (1980) Regional protein synthesis in rat 
brain following acute hemispheric ischemia. J. Neurochem. 35 1216-1226 
3 Hata, R., Maeda, K., Hermann., D and Hossmann, K.A. (2000) Evolution of brain 
infarction after transient cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 20 937-
946
4 Hermann, D.M., Kilic E., Hata R., Mies, G., and Hossmann, K.A. (2001) Relationship 
between metabolic dysfunctions, gene responses and delayed cell death after focal 
cerebral ischemia in mice. Neuroscience 104 947-955 
5 Rhoads. RE (1999) Signal transduction pathways that regulate eukaryotic protein 
synthesis J. Biol. Chem. 274 30337-30340 
6 Burda, J., Martin, M.E., Garcia, A., Alcazar, A., Fando, J.L. and Salinas, M. (1994) 
Phosphorylation of the D subunit of initiation factor 2 correlates with the inhibition of 
translation following transient cerebral ischaemia in the rat. Biochem. J. 302 335-338 
7 DeGracia, D.J., Adamczyk, S., Folbe, A.J., Konkoly, L.L., Pittman, J.E., Neumar, R.W., 
Sullivan, J.M., Scheuner, D., Kaufman, R.J., White, B.C. and  Krause, G.S. (1999) 
Eukaryotic initiation factor 2D kinase and phosphatase activity during postischemic brain 
reperfusion. Exp. Neurol. 155 221-227 
8 Kumar, R., Azam, S., Sullivan, J.M. , Owen, C.R., Cavener, D.R., Zhang, P., Ron, D., 
Harding, H.P., Chen, J.J., Han, A.,White, B.C., Krause, G.S. and DeGracia, D.J. (2001)
Brain ischemia and reperfusion activates the eukaryotic initiation factor 2D kinase, PERK 
J. Neurochem. 77 1418-1421
9 Paschen, W., Aufenberg, C., Hotop, S. and  Mengesdorf T. (2003) Transient cerebral 
ischemia activates processing of xbp1 messenger RNA indicative of endoplasmic 
reticulum stress. J. Cereb. Blood Flow Metab. 23 449-461 
10 Maus, M., Torrens, Y., Gauchy, C., Bretin, S., Nairn, A.C., Glowinski, J. and Premont, J. 
(2006) 2-Deoxyglucose and NMDA inhibit protein synthesis in neurons and regulate 
phosphorylation of elongation factor-2 by distinct mechanisms. J. Neurochem. 96 815-824 
11 DeGracia, D.J., Neumar, R.W., White, B.C. and Krause, G.S. (1996)  Global brain 
ischemia and reperfusion: modifications in eukaryotic initiations factors associated with 
inhibition of translation initiation. J. Neurochem. 67 2005-2012
12 Neumar, RW, DeGracia, D.J., White, B.C., McDermott, P.J., Evans, D.R. and Krause, 
G.S. (1995) Eukaryotic initiation factor 4E degradation during brain ischemia. J. 
Neurochem. 65 1391-1394
Biochemical Journal Immediate Publication. Published on 16 Jan 2008 as manuscript BJ20071060
TH
IS
 IS
 N
O
T 
TH
E 
FI
NA
L 
VE
RS
IO
N 
- s
ee
 d
oi
:1
0.
10
42
/B
J2
00
71
06
0
St
ag
e 2
(a)
PO
ST
-PR
INT
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2008 The Authors Journal compilation © 2008 Biochemical Society
12
13 Neumar, R.W., DeGracia, D.J., Konkoly, L.L., Khoury, J.I., White, B.C. and  Krause, 
G.S. (1998) Calpain mediates eukaryotic initiation factor 4G degradation during global 
brain ischemia. J. Cereb. Blood Flow Metab. 18, 876-881
14 Warner, D.S., Sheng, H. and Batinic-Haberle, I. (2004) Oxidants, antioxidants and the 
ischemic brain. J. Exp. Biol. 207, 3221 
15 DeGracia, D.J. and Montie, H.L. (2004) Cerebral ischemia and the unfolded protein 
response. J. Neurochem. 91, 1-8 
16 Uma, S., Yun, B.G. and Matt, R.L. (2001) The heme-regulated eukaryotic initiation factor 
2D kinase. J. Biol. Chem. 276, 14875-14883
17 Doutheil, J., Althausen, S., Treiman, M. and Paschen W (2000) Effect of nitric oxide on 
endoplasmic reticulum calcium homeostasis, protein synthesis and energy metabolism. 
Cell Calcium 27, 107-115 
18 Marin, P., Nastiuk, K.L., Daniel, N., Girault, J.A., Czernik, A.J., Glowinsky, J., Nairn, 
A.C. and Premont J. (1997) Glutamate-dependent phosphorylation of elongation factor-2 
and inhibition of protein synthesis in neurons. J. Neurosci. 17, 3445-3454 
19 Gauchy, C., Narin, A.C., Glowinski, J. and Premont J. (2002) N-methyl-D-aspartate 
receptor activation inhibits protein synthesis in cortical neurons independently of its ionic 
permeability properties. Neuroscience 114, 859-867
20 Petegnief, V., Friguls, B., Sanfeliu, C., Suñol C. and Planas, A.M. (2003) Transforming 
growth factor-D attenuates NMDA toxicity in cortical cultures by preventing protein 
synthesis inhibition through an Erk1/2-dependent mechanism. J. Biol. Chem.  278, 29552-
29559
21 Cossenza, M., Cadihle, D.V., Coutinho, R.N., Coutinho, R.N. and Paes-de-Carvalho, R. 
(2006) Inhibition of protein synthesis by activation of NMDA receptors in cultured retinal 
neurons: a new mechanism for the regulation of nitric oxide production. J. Neurochem. 
97, 1481-1493. 
22 Tremblay, R., Chakravarthy, B., Hewitt, K., Tauskela, J., Morley, P., Atkinson, T. and 
Durkin, J.P. (2000) Transient NMDA receptor inactivation provides long-term protection 
to cultured cortical neurons from a variety of death signals. J. Neurosci. 20, 7183-7192 
23 Morley, S.J., Coldwell, M.J., and Clemens, M.J. (2005) Initiation factor modifications in 
the preapototic phase. Cell Death Differ. 12, 571-584. 
24 Haghighat, A., Mader, S., Pause, A. and Sonenberg, N. (1995) Repression of cap-
dependent translation by 4E-binding protein 1: competition with p220 for binding to 
eukaryotic initiation factor-4E. EMBO J. 14, 5701-5709 
25 Mothe-Satney, I., Brunn, G.J., McMahon, L.P., Capaldo, C.T., Abraham, R.T. and 
Lawrence, J.C. Jr.  (2000) Mammalian target of rapamycin-dependent phosphorylation of 
PHAS-I in four (S/T)P sites detected by phosphor-specific antibodies. J. Biol. Chem. 275,
33836-33843.
Biochemical Journal Immediate Publication. Published on 16 Jan 2008 as manuscript BJ20071060
TH
IS
 IS
 N
O
T 
TH
E 
FI
NA
L 
VE
RS
IO
N 
- s
ee
 d
oi
:1
0.
10
42
/B
J2
00
71
06
0
St
ag
e 2
(a)
 PO
ST
-PR
INT
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2008 The Authors Journal compilation © 2008 Biochemical Society
13
26 Wang, X., Beugnet, A., Murakami, M., Yamanaka, S. and Proud, C.G. (2005) Distinct 
signaling events downstream of mTOR cooperate to mediate the effects of amino acids 
and insulin on initiation factor 4E-binding proteins. Mol. Cell. Biol. 25, 2558-2578. 
27 Lin, T.A., Kong. X., Haystead, T.A., Pause, A., Belsham, G., Sonenberg, N. and 
Lawrence, J.C. Jr (1994) PHAS-I as a link between mitogen-activated protein kinase and 
translation initiation. Science 266, 653-656 
28 Pause, A., Belsham, G.J., Gingras, A.C., Donze, O., Lin, T.A,. Lawrence, J.C. Jr, and 
Sonenberg, N. (1994) Insulin-dependent stimulation of protein synthesis by 
phosphorylation of a regulator of 5’-cap function. Nature 371, 762-767 
29 Karim, M.M., Hughes, J.M.X., Warwicker, J., Scheper, G.C., Proud, C.G. and McCarthy, 
J.E.G. (2001) A quantitative molecular model for modulation of mammalian translation 
by the eIF4E-binding protein 1. J. Biol. Chem. 276, 20750-20757 
30 Proud, C.G. (2007) Signalling to translation: how signal transduction pathways control the 
protein synthetic machinery. Biochem. J. 403, 217-234 
31 Gingras, A.C., Raught, B., Gygi, S.P., Niedzviewiecka, A., Miron, M., Burley, S.K., 
Polakiewicz, R.D.,  Wyslouch-Cieszynska, A., Aebersold, R., and Sonenberg, N. (2001) 
Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes & Dev 15, 2852-
2864
32 Martin de la Vega, C., Burda, J., Nemethova, M., Quevedo, C., Alcazar, A., Martin, M.E., 
Danielisova, V., Fando, J.L. and Salinas, M. (2001) Possible mechanisms involved in the 
down-regulation of translation during transient global ischaemia in the rat brain. Biochem. 
J. 357, 819-826
33 Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J.W., Wang, Y.T., Salter, 
M.W. and Tymianski, M. (2002) Treatment of ischemic brain damage by perturbating 
NMDA receptor- PSD-95 protein interactions. Science 298, 846-850
34 Dawson, V.L., Dawson, T.M., Bartley, D.A., Uhl, G.R. and Snyder, S.H. (1993) 
Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J. Neurosci. 
13, 2651-2661 
35 Bonfoco, E., Leist, M., Zhivotovsky, B., Orrenius, S., Lipton, S.A., and Nicotera, P. 
(1996) Cytoskeletal breakdown and apoptosis elicited by NO donors in cerebellar granule 
cells require NMDA receptor activation. J. Neurochem. 67, 2484-2493 
36 Golde, S., Chandran, S., Brown, G.C. and Compston, A. (2002) Different pathways for 
iNOS-mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor 
expression. J. Neurochem. 82, 269–282. 
37 Bal-Price, A. and Brown, G.C. (2001) Inflammatory neurodegeneration mediated by nitric 
oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and 
excitotoxicity. J. Neurosci. 21, 6480–6491 
Biochemical Journal Immediate Publication. Published on 16 Jan 2008 as manuscript BJ20071060
TH
IS
 IS
 N
O
T 
TH
E 
FI
NA
L 
VE
RS
IO
N 
- s
ee
 d
oi
:1
0.
10
42
/B
J2
00
71
06
0
St
ag
e 2
(a)
 PO
ST
-PR
INT
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2008 The Authors Journal compilation © 2008 Biochemical Society
14
38 Pall, M.L. (2002) NMDA sensitization and stimulation by peroxinitrite, nitric oxide and 
organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity. 
FASEB J. 16, 1407-1417
39 Volbracht, C., Chua, B.T., Ng, C.P., Bahr, B.A., Hong, W. and Li, P. (2005) The critical 
role of calpain versus caspase activation in excitotoxic injury induced by nitric oxide. J. 
Neurochem. 93, 1280-1292 
40 Brorson, J.R.,  Schumacker, P.T.,  and Zhang, H. (1999) Nitric oxide acutely inhibits 
neuronal energy production. J. Neurosci. 19, 147-156 
41 Meli, E., Pangallo, M., Baronti, R., Chiarugi, A., Cozzi, A., Domenico E. Pellegrini-
Giampietro, D.E., and Moroni F. (2003) Poly(ADP-ribose) polymerase as a key player in 
excitotoxicity and post-ischemic brain damage. Toxicol. Lett. 139:153-162
42 Muñoz, F., Martín, M.E.,  Manso-Tomico, J., Berlanga, J., Salinas, M., and Fando, J. L. 
(2000) Ischemia-induced phosphorylation of initiation factor 2 in differentiated PC12 
cells: role for initiation factor 2 phosphatase. J. Neurochem. 75, 2335–2345
43 Moore, J.D., Rothwell, N.J. and Gibson, R.M. (2002) Involvement of caspases and 
calpains in cerebrocortical neuronal cell death is stimulus-dependent. Br. J. Pharmacol. 
35, 1069-1077 
44 Sattler, R., Xiong, Z., Lu, W.Y., Hafner, M., MacDonald, J.F. and Tymianski, M. (1999) 
Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 
protein. Science 284, 1845-1848 
45 Dawson, V., Kizushi, V.M., Huang, P.L., Snyder, S.H. and Dawson, T.M. (1996) 
Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-
deficient mice. J. Neurosci. 16, 2479-2487 
46 DeGracia, D.J. (2004) Acute and persistent protein synthesis inhibition following cerebral 
reperfusion. J. Neurosci. Res. 77, 771-776
47 García, L., Burda, J., Hrehorovska, M., Burda, R., Martin, M.E. and Salinas, M. (2004) 
Ischaemic preconditioning in the rat brain: effect on the activity of several initiation 
factors, Akt and extracellular signal-regulated protein kinase phosphorylation, and GRP78 
and GADD34 expression. J. Neurochem. 88, 136-147 
48 Planas, A.M., Soriano, M.A., Estrada, A., Sanz, O., Martin, F. and Ferrer, I. (1997) The 
heat shock stress response after brain lesions: induction of 72 kDa heat shock protein (cell 
types involved, axonal transport, transcriptional regulation) and protein synthesis 
inhibition. Progress Neurobiol. 51, 607-636. 
49 Piñeiro, D., González, V.M., Hernández-Jiménez, M., Salinas, M, and Martin, M.E. 
(2007) Translation regulation after taxol treatment in NIH3T3 cells involves the 
elongation factor (eEF)2. Exp. Cell Res. 313, 3694-3706. 
Biochemical Journal Immediate Publication. Published on 16 Jan 2008 as manuscript BJ20071060
TH
IS
 IS
 N
O
T 
TH
E 
FI
NA
L 
VE
RS
IO
N 
- s
ee
 d
oi
:1
0.
10
42
/B
J2
00
71
06
0
S
ag
 2(
a) 
PO
ST
-PR
INT
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2008 The Authors Journal compilation © 2008 Biochemical Society
15
50 García-Bonilla, L., Burda, J., Piñeiro, D., Ayuso, I., Gómez-Calcerrada, M. and Salinas, 
M. (2006) Calpain-induced proteolysis after transient global cerebral ischemia and 
ischemic tolerance in a rat model. Neurochem. Res. 31, 1433-1441. 
Biochemical Journal Immediate Publication. Published on 16 Jan 2008 as manuscript BJ20071060
TH
IS
 IS
 N
O
T 
TH
E 
FI
NA
L 
VE
RS
IO
N 
- s
ee
 d
oi
:1
0.
10
42
/B
J2
00
71
06
0
St
ag
e 2
(a)
 PO
ST
-PR
INT
Licenced copy. Copying is not permitted, except with prior permission and as allowed by law.
© 2008 The Authors Journal compilation © 2008 Biochemical Society
16
Figure legends 
Figure 1 Neuronal death induced by NMDA and NO
A. Neuron-enriched cortical cultures at 11-12 DIV were co-incubated with 2 mM L-NAME 
plus 100 µM NPLA (NOSI) and NMDA for 30 min. Medium was then removed and replaced 
with fresh medium supplemented with the same concentration of NOS inhibitors. Lactate 
dehydrogenase activity was determined 24 h later as indicated in Methods. Values in arbitrary 
units are mean ± SEM of 4-8 individual determinations. B. Mixed cultures were treated with 
NMDA and NOSI as indicated in A. At 24 h post-injury, cells were fixed and stained with PI 
as indicated in Methods. The number of PI-stained nuclei was counted under the fluorescence 
microscope (see Methods). Results are expressed as PI-positive neurons/mm2. Values are 
mean ± SEM of 6 replicates per condition from two different experiments. C. Dose-response 
study (4-40 PM) for DEA/NO toxicity in mixed cultures. Lactate dehydrogenase activity was 
determined in culture media 24 h after a 30-min exposure to DEA/NO. Values are mean ± 
SEM of 7-8 replicates from two different experiments. Significance for all graphs:*P<0.05, 
***P<0.001 vs. control cultures; $$$P<0.001 vs. NMDA-treated cultures. C=control, 
N=NMDA, NOSI=NOS inhibitors (NAME+NPLA). N+NOSI=NMDA+NOS inhibitors. 
Figure 2 Long-lasting inhibition of protein synthesis induced by NMDA and NO in 
cortical cultures 
A. Protein synthesis was assessed by incorporation of [3H]leucine into proteins in mixed 
cultures as detailed in Methods. [3H]leucine was added simultaneously with NMDA (0.5 h), 
30 min (1 h) or 90 min (2 h) after a 30-min incubation with NMDA. NOS inhibitors were 
added immediately before NMDA and after NMDA removal. Results were calculated as 
dpm/mg prot/min and expressed as % control (n=4-16). B. Incorporation of [3H]leucine into 
proteins in neuron cultures was performed as for mixed cultures and detailed in Methods. 
Data are mean ± SEM (n=4-15). C. Protein synthesis was assessed by incorporation of 
[3H]leucine into proteins in neuron cultures as detailed in Methods. [3H]leucine was added 
simultaneously with DEA/NO (0.5 h) or 90 min (2 h) after a 30-min incubation with DEA/NO 
40 PM. Results were calculated as dpm/mg prot/min and expressed as % control. Data are 
mean ± SEM (n=9-17). Significance for all graphs: *P<0.05, **P<0.01, ***P<0.001 vs. 
control cultures; $$$P<0.001 vs. NMDA-treated cultures. C=control, N=NMDA, NOSI=NOS 
inhibitors (NAME+NPLA), N+NOSI=NMDA+NOS inhibitors. Bars in the graphs represent 
the incubation duration with NMDA or DEA/NO. 
Figure 3 Effect of NMDA and NO on ATP content and phosphorylation status of eIF2D
A. Neuron-enriched cultures were incubated for 30 min with NMDA. Cells were scrapped 
either at the end of the 30-min incubation (0.5 h) or 90 min after medium change (2 h) and 
processed for ATP determination as detailed in Methods. Results were calculated as nmol/mg 
protein and expressed as % control. Data are mean ± SEM of 8-18 replicates. B. Neuron-
enriched cultures were treated for 30 min with DEA/NO. ATP content was determined at 0.5 
h or 2 h after DEA/NO as in A. Data are mean ± SEM of 10-20 replicates from three different 
experiments. C. Neuron-enriched cultures were co-incubated for 30 min with NMDA and 
NOS inhibitors. Cells were scraped 90 min after medium change and processed for ATP 
determination as detailed in A. Data are mean ± SEM of 9 replicates for each condition from 
two different experiments. Neuron-enriched cultures were treated with NMDA or 
NMDA+NOSI (D) or with DEA/NO (E) for 30 min. Ninety minutes later, cells were 
collected, proteins were separated on 12% SDS-PAGE and processed for Western blot as 
indicated in Methods. Membranes were incubated first with an eIF2D-P antibody and then 
reprobed with the antibody recognizing eIF2D independently of its phosphorylation state. 
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Bottom panels are quantitative analysis of the blots. Band density was measured, the eIF2D-
P/eIF2D total ratio was calculated for each sample and results are expressed as % control. 
Data are mean ± SEM of 11-13 replicates in D and 9-12 replicates in E. Significance for all 
graphs: *P<0.05, ***P<0.001 vs. control cultures; $$P<0.01 vs. NMDA-treated cultures. 
Unpaired t-test was performed for statistical analysis in E. F. Neurons were treated with 
thapsigargin for 30 min and phosphorylation of eIF2D was examined by Western blot as 
described in D. C=control, N=NMDA, N+NOSI=NMDA+NOS inhibitors (NAME+NPLA), 
Thap=thapsigargin.
Figure 4 D-spectrin and eIF4G cleavage after NMDA and NO 
A. NMDA leads to the proteolysis of D-spectrin and eIF4G. Neuron cultures were exposed to 
NMDA or NMDA+NOS inhibitors for 30 min as in Fig 3D. Proteins were separated on 7% 
SDS-PAGE and processed for eIF4G immunoblotting. Membranes were then reprobed with 
an antibody recognizing D-spectrin. NMDA treatment induced a loss of eIF4G (bottom blot) 
and of full-length D-spectrin and the generation of the 150 kDa spectrin fragment but not of 
the 120 kDa product (lowest band, top blot). NOS inhibitors impeded spectrin and eIF4G 
proteolysis. B. Neuron cultures were exposed for 30 min to DEA/NO as in Figure 3E. 
Proteins were processed for eIF4G and D-spectrin Western blot as in A. DEA/NO triggered 
calpain-mediated breakdown of spectrin (top blot) and eIF4G (bottom blot). Blots are 
representative of two different experiments. C. Quantitative analysis of cleaved spectrin (top 
graph) and eIF4G (bottom graph). Cells were treated as in A. Results were calculated as 
arbitrary units and expressed as % control. Data are mean ± SEM of 4-6 replicates for spectrin 
and 8-13 for eIF4G. D. Quantitative analysis of cleaved eIF4G after DEA/NO treatment. Cells 
were treated as in B. Data are mean ± SEM of 7 replicates. Significance for all 
graphs:*P<0.05, **P<0.01 vs. control cultures and $P<0.05, $$$P<0.001 vs. NMDA-treated 
cultures. C=control, N=NMDA, N+NOSI=NMDA+NOS inhibitors (NAME+NPLA).  
Figure 5 Effect of calpain inhitors on D-spectrin and eIF4G cleavage 
A. Neuron-enriched cultures were pre-treated for 1 h with 30 µM calpeptin and exposed to 
NMDA for 30 min. B. Neuron-enriched cultures were pre-treated for 1 h with 30 µM 
MDL28170 and then exposed to DEA/NO. Sister cultures were treated with vehicle. Ninety 
minutes after medium change, cells were collected and processed for eIF4G and D-spectrin 
Western blot as in Figure 4. The calpain inhibitors completely blocked spectrin and eIF4G 
proteolysis. C. Quantitative analysis of cleaved spectrin (top graph) and eIF4G (bottom 
graph). Cells were treated as in A. Data are mean ± SEM of 5 replicates for spectrin and 9-10 
for eIF4G. D. Quantitative analysis of cleaved spectrin (top graph) and eIF4G (bottom graph). 
Cells were treated as in B. Data are mean ± SEM of 9-10 replicates. Significance for all 
graphs: *P<0.05, ***P<0.001 vs. control cultures and $P<0.05, $$P<0.01 or $$$P<0.001 vs. 
NMDA- or DEA/NO-treated cultures. C=control, N=NMDA, N+NOSI=NMDA+NOS 
inhibitors (NAME+NPLA), D=DEA/NO, Cp= calpeptin and M=MDL28170.
Figure 6 Phosphorylation status of 4E-BP1 and eIF4E/eIF4G complexes formation after 
NMDA and NO. Effect of calpain inhibitors on 4E-BP1 dephosphorylation and protein 
synthesis inhibition induced by NMDA or DEA/NO. 
A. Neuron-enriched cultures were treated with NMDA or NMDA+NOS inhibtors for 30 min 
and 90 min after medium change, cells were collected and processed for eIF4E Western blot. 
B. Cultures were pretreated for 1 h with 30 µM calpeptin or MDL28170. Then NMDA or 
DEA/NO were added to the culture medium. Thirty minutes later, medium was changed and 
replaced with fresh medium containing the same concentration of calpain inhibitors. Sister 
cultures were treated with NMDA or NMDA+NOS inhibitors. Ninety minutes after medium 
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change, cells were collected and processed for 4E-BP1 Western blot. C.  Cultures were treated 
with NMDA or NMDA+NOS inhibitors or DEA/NO.  Ninety minutes after NMDA or 
DEA/NO exposure, cells were processed for the purification of eIF4E by m7GTP-sepharose
affinity chromatography. Proteins were then eluted in SDS loading buffer and subjected to 
7.5%-17% SDS-PAGE followed by Western blot for eIF4G, eIF4E and 4E-BP1, as described 
in Methods. D. Neuron-enriched cultures were pre-treated for 1 h with 30 µM calpeptin or 
MDL28170. NMDA or DEA/NO were then added to the culture medium. Thirty minutes 
later, the medium was changed and replaced with fresh medium containing the same 
concentration of calpain inhibitors. Ninety minutes after medium change, cells were incubated 
for 30 min with [3H]leucine and then processed for the determination of leucine incorporated 
into proteins, as detailed in Methods. Results calculated in dpm/mg prot/min are presented as 
mean ± SEM of 4-9 replicates from two different cultures. None of the calpain inhibitors 
impeded NMDA- or DEA/NO-induced translation inhibition. E. Cultures were treated as in 
D. LDH activity was determined 24 h later. Results proceeding from two different 
experiments are expressed in arbitrary units. Data are mean ± SEM of 7-16 replicates. None 
of the inhibitors enabled rescue from neuronal death induced by NMDA or DEA/NO. 
Significance for both graphs: ***P<0.001 vs. control cultures; $P<0.05 vs. NMDA-treated 
cultures. C=control, N=NMDA, N+NOSI=NMDA+NOS inhibitors (NAME+NPLA), 
D=DEA/NO, Cp=calpeptin, M=MDL28170.  
Figure 7 Effect of rapamycin on phosphorylation status of 4E-BP1, eIF4E/eIF4G 
complexes formation and protein synthesis
Neuron-enriched cultures were treated for 3 h with rapamycin (1 or 2 PM) or vehicle and 
were then processed for eIF4G or 4E-BP1 Western blot (A) or for eIF4E purification and 
subsequent determination of the eIF4E/eIF4G and eIF4E/4E-BP1 complexes (B). C. Protein 
synthesis was assessed by incorporation of [3H]leucine into proteins in neuron cultures 3 h 
after addition of rapamycin (1 or 2 PM) or vehicle as detailed in Methods. Results were 
calculated as dpm/mg prot/min and expressed as % control (n=5-11). Significance: **P<0.01 
and **P<0.001 vs. control cultures. Rap=rapamycin. 
Figure 8 NMDA targets responsible for delayed translation repression  
Following the stimulation of NMDA receptors, NO is produced and induces the 
hypophosphorylation of 4E-BP1 and the subsequent binding to eIF4E, thus reducing its 
availability to interact with eIF4G. Increased intracellular calcium activates calpain that 
cleaves eIF4G into fragments unable to bind eIF4E. Lower amounts of full-length eIF4G 
together with the sequestration of eIF4E result in the formation of fewer eIF4E/eIF4G 
complexes and translation inhibition. Alterations of additional translation factors by 
regulation of phosphorylation status and/or degradation most likely contribute to achieve the 
full inhibition of translation. 
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Table 1 Phosphorylation status of 4E-BP1 after NMDA and NO. Effect of calpain or 
NOS inhibitors 
  Isoforms  
 Gamma Beta Alpha 
Control 34.9r5.6 42.9r4.7 22.2r4.7
NMDA 28.3r5.2 39.7r4.9 32.0r5.4**
NMDA+NOSI 39.4r5.6$$ 42.3r4.1 18.3r4.4$$$
DEA/NO 24.4r6.2** 38.8r2.7 36.8r3.8***
    
Control 39.1 r1.7 39.9r1.6 20.4r0.8
NMDA 30.0r2.9 41.0r1.2 29.0r2.0*
NMDA+Calpeptin 23.2r2.3*** 40.4r0.9 36.4r2.3***,$
    
Control 33.2r1.4 43.8r1.3 23.0r1.7
DEA/NO 23.3r1.7* 40.9r0.6 35.9r1.7**
DEA/NO+MDL28170 22.6r3.6* 39.9r0.7* 37.5r3.6**
Neuron-enriched cultures were treated with NMDA, NMDA+NOS inhibitors or DEA/NO for 
30 min. Calpain inhibitors were added as described in Figure 5. Ninety minutes after NMDA 
or DEA/NO removal, cells were collected and processed for 4E-BP1 Western blot. For each 
sample, the proportion of each phosphorylated form of 4E-BP1 (Į, ȕ and Ȗ) was calculated as 
the percentage of each band over the total as explained in Methods. Data are mean ± SEM of 
5-10 replicates. Significance: *P<0.05, **P<0.01, ***P<0.001 vs. control cultures and 
$P<0.05, $$P<0.01 or $$$P<0.001 vs. NMDA-treated cultures. NOSI=NOS inhibitors.
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